Razanne Oueini

1 week ago | drugtopics.com | Killian Meara |Razanne Oueini

The Pharmacy Quality Alliance (PQA) developed the Persistence to Basal Insulin (PST-INS) measure to track patients who maintain consistent basal insulin use over a year. Endorsed in 2021, it is now used in Medicare Part D performance and safety evaluations. The measure, based on a 2014 validated methodology, is linked to better outcomes like lower A1c, fewer hospitalizations, and reduced ER visits. In 2023, insulin costs were capped at $35 for Medicare enrollees under the Inflation Reduction Act.

2 weeks ago | drugtopics.com | Killian Meara |Razanne Oueini

The Pharmacy Quality Alliance (PQA) developed the Persistence to Basal Insulin (PST-INS) measure through its systematic, consensus-based process, beginning in 2018. Endorsed in 2021, the measure has since been adopted in the Medicare Part D program and included in patient safety reports and the Medicare Part D display page for 2024 and 2025. It assesses the percentage of individuals aged 18 or older who remained persistent with basal insulin therapy over a measurement year.